JP2019536768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536768A5 JP2019536768A5 JP2019523838A JP2019523838A JP2019536768A5 JP 2019536768 A5 JP2019536768 A5 JP 2019536768A5 JP 2019523838 A JP2019523838 A JP 2019523838A JP 2019523838 A JP2019523838 A JP 2019523838A JP 2019536768 A5 JP2019536768 A5 JP 2019536768A5
- Authority
- JP
- Japan
- Prior art keywords
- tetrahydro
- indazole
- naphthylidine
- ethoxy
- propanoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 190
- 235000019260 propionic acid Nutrition 0.000 claims 162
- -1 cyano, hydroxyl Chemical group 0.000 claims 154
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 143
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 134
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 29
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 16
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 206010016654 Fibrosis Diseases 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 230000004761 fibrosis Effects 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000004103 aminoalkyl group Chemical group 0.000 claims 11
- 125000004452 carbocyclyl group Chemical group 0.000 claims 11
- 125000004438 haloalkoxy group Chemical group 0.000 claims 9
- 125000001188 haloalkyl group Chemical group 0.000 claims 9
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 229940124530 sulfonamide Drugs 0.000 claims 7
- 150000003456 sulfonamides Chemical class 0.000 claims 7
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 6
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 6
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 6
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 5
- 150000001408 amides Chemical class 0.000 claims 5
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 206010023421 Kidney fibrosis Diseases 0.000 claims 3
- 230000001476 alcoholic effect Effects 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 claims 3
- 208000006454 hepatitis Diseases 0.000 claims 3
- 231100000283 hepatitis Toxicity 0.000 claims 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 3
- 239000001294 propane Substances 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 claims 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 2
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 2
- IRBNGLACBFFCAF-NRFANRHFSA-N (3S)-3-[5-[2-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)ethoxy]indazol-1-yl]-3-(6-methoxypyridin-3-yl)propanoic acid Chemical compound O1C2=C(NCC1)N=C(C=C2)CCOC=1C=C2C=NN(C2=CC=1)[C@@H](CC(=O)O)C=1C=NC(=CC=1)OC IRBNGLACBFFCAF-NRFANRHFSA-N 0.000 claims 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- RZHGYJCHLYTNLF-UHFFFAOYSA-N 3-[5-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]indazol-1-yl]-3-(6-methoxypyridin-3-yl)propanoic acid Chemical compound N1C(=NCC1)NCCOC=1C=C2C=NN(C2=CC=1)C(CC(=O)O)C=1C=NC(=CC=1)OC RZHGYJCHLYTNLF-UHFFFAOYSA-N 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims 1
- 125000003627 8 membered carbocyclic group Chemical group 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 239000001273 butane Substances 0.000 claims 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 claims 1
- 150000004657 carbamic acid derivatives Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662418842P | 2016-11-08 | 2016-11-08 | |
| US62/418,842 | 2016-11-08 | ||
| PCT/US2017/060386 WO2018089357A1 (en) | 2016-11-08 | 2017-11-07 | INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019536768A JP2019536768A (ja) | 2019-12-19 |
| JP2019536768A5 true JP2019536768A5 (enExample) | 2020-12-17 |
| JP7213804B2 JP7213804B2 (ja) | 2023-01-27 |
Family
ID=60409436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019523838A Active JP7213804B2 (ja) | 2016-11-08 | 2017-11-07 | αＶインテグリンアンタゴニストとしてのインダゾール誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10745384B2 (enExample) |
| EP (1) | EP3538519B1 (enExample) |
| JP (1) | JP7213804B2 (enExample) |
| KR (1) | KR102506327B1 (enExample) |
| CN (1) | CN110214137A (enExample) |
| AU (1) | AU2017359027A1 (enExample) |
| CA (1) | CA3042714A1 (enExample) |
| EA (1) | EA201991123A1 (enExample) |
| ES (1) | ES2886650T3 (enExample) |
| IL (1) | IL266472A (enExample) |
| MA (1) | MA46745A (enExample) |
| MX (1) | MX378565B (enExample) |
| WO (1) | WO2018089357A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| EA201991123A1 (ru) * | 2016-11-08 | 2019-11-29 | ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV | |
| CA3045491A1 (en) | 2016-12-29 | 2018-07-19 | Indalo Therapeutics, Inc. | Integrin antagonists |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| EP4159727B1 (en) | 2017-02-28 | 2026-04-08 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| PT3844162T (pt) | 2018-08-29 | 2025-03-28 | Morphic Therapeutic Inc | Inibidores da integrina alfa v beta6 |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| AU2019327475B2 (en) | 2018-08-29 | 2025-06-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| WO2020092401A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN |
| WO2020092394A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| ES2987796T3 (es) | 2018-10-30 | 2024-11-18 | Gilead Sciences Inc | Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias |
| DK3873884T3 (da) | 2018-10-30 | 2025-02-17 | Gilead Sciences Inc | 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme |
| AU2020329207B2 (en) | 2019-08-14 | 2024-02-29 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| KR102048050B1 (ko) * | 2019-08-29 | 2020-01-22 | 대한민국 | Adb-푸비나카의 대사체 합성 방법 |
| EP4034236A1 (en) | 2019-09-26 | 2022-08-03 | Abionyx Pharma SA | Compounds useful for treating liver diseases |
| WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| EP4317145A4 (en) * | 2021-03-24 | 2025-03-12 | Shionogi & Co., Ltd | Pharmaceutical composition containing glp-1 receptor agonist having fused ring |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| CA2240439A1 (en) * | 1995-12-22 | 1997-07-03 | The Dupont Merck Pharmaceutical Company | Novel integrin receptor antagonists |
| ZA972195B (en) | 1996-03-15 | 1998-09-14 | Du Pont Merck Pharma | Spirocycle integrin inhibitors |
| JP2001524481A (ja) | 1997-11-26 | 2001-12-04 | デュポン ファーマシューティカルズ カンパニー | αＶβ３アンタゴニストとしての１，３，４−チアジアゾール類および１，３，４−オキサジアゾール類 |
| EP1047425A4 (en) | 1997-12-17 | 2009-04-22 | Merck & Co Inc | INTEGRIN RECEPTOR ANTAGONISTS |
| AU748621B2 (en) | 1998-08-13 | 2002-06-06 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6921767B2 (en) | 2000-06-15 | 2005-07-26 | Pharmacia Corporation | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives |
| WO2002060438A1 (en) * | 2001-01-29 | 2002-08-08 | 3-Dimensional Pharmaceuticals, Inc. | Substituted indoles and their use as integrin antagonists |
| US6872730B2 (en) * | 2001-04-27 | 2005-03-29 | 3-Dimensional Pharmaceuticals, Inc. | Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists |
| AU2002319282B2 (en) * | 2001-08-01 | 2007-06-28 | Merck Patent Gmbh | Integrin inhibitors for the treatment of eye diseases |
| WO2006108040A1 (en) | 2005-04-05 | 2006-10-12 | Janssen Pharmaceutica, N.V. | Substituted indoles and their use as integrin antagonists |
| JP2009539815A (ja) | 2006-06-09 | 2009-11-19 | アストラゼネカ アクチボラグ | 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物 |
| WO2008125811A1 (en) | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
| ITFI20100019A1 (it) | 2010-02-12 | 2011-08-13 | Univ Firenze | Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori. |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| JP6387100B2 (ja) | 2014-08-08 | 2018-09-05 | 株式会社Ｆｕｊｉ | スクリーン印刷装置 |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EP3925959A1 (en) | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
| AU2016228852A1 (en) | 2015-03-10 | 2017-10-19 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| EA201991123A1 (ru) * | 2016-11-08 | 2019-11-29 | ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV |
-
2017
- 2017-11-07 EA EA201991123A patent/EA201991123A1/ru unknown
- 2017-11-07 MX MX2019005243A patent/MX378565B/es unknown
- 2017-11-07 MA MA046745A patent/MA46745A/fr unknown
- 2017-11-07 KR KR1020197016080A patent/KR102506327B1/ko active Active
- 2017-11-07 ES ES17801234T patent/ES2886650T3/es active Active
- 2017-11-07 CA CA3042714A patent/CA3042714A1/en not_active Abandoned
- 2017-11-07 AU AU2017359027A patent/AU2017359027A1/en not_active Abandoned
- 2017-11-07 JP JP2019523838A patent/JP7213804B2/ja active Active
- 2017-11-07 CN CN201780082125.5A patent/CN110214137A/zh not_active Withdrawn
- 2017-11-07 WO PCT/US2017/060386 patent/WO2018089357A1/en not_active Ceased
- 2017-11-07 EP EP17801234.0A patent/EP3538519B1/en active Active
- 2017-11-07 US US16/347,831 patent/US10745384B2/en active Active
-
2019
- 2019-05-06 IL IL266472A patent/IL266472A/en unknown
-
2020
- 2020-07-09 US US16/924,346 patent/US11028071B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11591336B2 (en) | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors | |
| AU776077B2 (en) | Use of CRF antagonists and related compositions | |
| RU2007107910A (ru) | Гетероциклические соединения | |
| ES2620612T3 (es) | Derivados de sulfóxidos y sulfonas de piridinilo y pirimidinilo | |
| US20240059703A1 (en) | Heterocyclic spiro compounds and methods of use | |
| JP2016520116A5 (enExample) | ||
| EA025520B1 (ru) | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
| JP2014518267A5 (enExample) | ||
| JP2018529731A5 (enExample) | ||
| JP2014503544A5 (enExample) | ||
| JP2023549055A5 (enExample) | ||
| JP6695353B2 (ja) | Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体 | |
| JP2009522206A5 (enExample) | ||
| JP2011506417A5 (enExample) | ||
| JP2017535561A5 (enExample) | ||
| JP2018501315A5 (enExample) | ||
| JP2004527560A5 (enExample) | ||
| JP2016537384A5 (enExample) | ||
| JP2017531039A5 (enExample) | ||
| JP2013500247A5 (enExample) | ||
| MX2012005284A (es) | Compuestos y metodos para la modulacion de cinasas. e indicaciones para ello. | |
| JP2013521285A5 (enExample) | ||
| JP2014513139A5 (enExample) | ||
| JP2017513887A5 (enExample) | ||
| RU2010128543A (ru) | Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов |